Research Analysts Offer Predictions for NMRA FY2030 Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Neumora Therapeutics in a note issued to investors on Monday, January 26th. HC Wainwright analyst D. Tsao forecasts that the company will earn $2.02 per share for the year. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share.

Several other research firms also recently weighed in on NMRA. Leerink Partners started coverage on Neumora Therapeutics in a report on Monday, January 12th. They issued an “outperform” rating and a $8.00 price objective for the company. Mizuho set a $6.00 price target on shares of Neumora Therapeutics in a research note on Monday, January 5th. Royal Bank Of Canada raised shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and raised their price objective for the stock from $4.00 to $7.00 in a research report on Monday, December 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Thursday, January 22nd. Finally, Needham & Company LLC increased their target price on shares of Neumora Therapeutics from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Tuesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Neumora Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $8.13.

Neumora Therapeutics Stock Performance

NASDAQ:NMRA opened at $2.04 on Tuesday. Neumora Therapeutics has a 12 month low of $0.61 and a 12 month high of $3.25. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.85 and a quick ratio of 6.85. The firm has a market capitalization of $340.86 million, a PE ratio of -1.39 and a beta of 3.22. The business’s fifty day moving average price is $2.04 and its 200 day moving average price is $1.98.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Thursday, November 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01).

Institutional Investors Weigh In On Neumora Therapeutics

Large investors have recently added to or reduced their stakes in the business. Legacy Private Trust Co. acquired a new stake in Neumora Therapeutics during the third quarter worth approximately $25,000. CWM LLC boosted its holdings in shares of Neumora Therapeutics by 41.8% during the second quarter. CWM LLC now owns 35,750 shares of the company’s stock worth $26,000 after purchasing an additional 10,537 shares during the last quarter. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Neumora Therapeutics in the second quarter valued at $29,000. Virtu Financial LLC acquired a new position in Neumora Therapeutics in the third quarter valued at $31,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Neumora Therapeutics during the second quarter worth about $41,000. 47.65% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Neumora Therapeutics

In other news, insider Daljit Singh Aurora sold 114,703 shares of the company’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $2.68, for a total transaction of $307,404.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 26.80% of the stock is currently owned by company insiders.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.